Last reviewed · How we verify
autologous T cells & cyclophosphamide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
autologous T cells & cyclophosphamide (autologous T cells & cyclophosphamide) — Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| autologous T cells & cyclophosphamide TARGET | autologous T cells & cyclophosphamide | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- autologous T cells & cyclophosphamide CI watch — RSS
- autologous T cells & cyclophosphamide CI watch — Atom
- autologous T cells & cyclophosphamide CI watch — JSON
- autologous T cells & cyclophosphamide alone — RSS
Cite this brief
Drug Landscape (2026). autologous T cells & cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-t-cells-cyclophosphamide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab